Using SSRIs for Ejaculation Control and What Off Label Prescribing Means
- Explains the misconception at the centre of this topic: the one licensed medicine is itself an SSRI, just a short acting one.
- Sets out what off label prescribing actually means, who carries the decision, and what to ask before agreeing to it.
- Covers withdrawal effects using the regulator's own wording, which almost no page on this subject includes.
- States plainly what the evidence does not show, including that no trial has compared these options against each other.
SSRIs are used to delay ejaculation, and all but one of them are prescribed off label for it. The one that is licensed for premature ejaculation is itself an SSRI, which is the fact that reframes this whole subject.
Selective serotonin reuptake inhibitors are a class of medicine developed for depression and anxiety. The National Institute for Health and Care Excellence describes the licensed premature ejaculation medicine, dapoxetine, as a short acting selective serotonin reuptake inhibitor. So the choice is not between an SSRI and a proper treatment. It is between a short acting SSRI with a licence and longer acting SSRIs without one.
That distinction runs through everything below: why these medicines delay ejaculation, what off label prescribing means, what the adverse effects and withdrawal effects are, and where the evidence simply stops. This page gives no dose and no schedule for any medicine. Those come from your prescriber and from the patient information leaflet in your pack.
Key things to know
- The licensed premature ejaculation medicine is a short acting SSRI. Longer acting SSRIs used for the same purpose are prescribed outside their licences.
- Off label means the medicine is licensed for something else and is being used for this instead. The prescriber carries that decision and should explain it.
- SSRIs delay ejaculation by inhibiting serotonin reuptake, which raises the threshold at which the ejaculatory reflex fires.
- Delayed or abnormal ejaculation is listed by the regulator as a very common or common adverse effect of SSRIs, which is the same effect being used deliberately here.
- No head to head trial compares these medicines against each other for this use, so no ranking of them exists in the UK regulator record.
- Stopping a daily SSRI abruptly can produce withdrawal effects. That is a conversation to have with your prescriber before you stop, not afterwards.
- Treatment suitability depends on an individual clinical assessment.
Why SSRIs delay ejaculation
SSRIs increase the amount of serotonin available between nerve cells, which raises the threshold at which the ejaculatory reflex fires. Serotonin is also written 5 HT, and the neurons that release it sit within the central nervous system, including the reflex pathways in the spinal cord. More 5 HT at the receptors means a higher threshold, and a higher threshold means a longer ejaculation latency.
Not every 5 HT receptor pulls in the same direction, which is why the picture is less tidy than it sounds. Activity at the 5 HT1A receptor is associated with shorter latency, while activity at other subtypes is associated with longer latency. SSRIs raise 5 HT across all of them at once, so the net effect is a balance rather than a single switch, and that is part of why response varies so much between men.
What the regulator actually says about the mechanism
The National Institute for Health and Care Excellence describes the effect of the licensed medicine as presumed to be linked to the inhibition of neuronal reuptake of serotonin and the subsequent potentiation of the neurotransmitter's action at pre and postsynaptic receptors.
The word presumed is doing real work in that sentence. Serotonergic neurotransmission is a well supported explanation rather than a directly demonstrated pathway in people. The studies mapping the ejaculatory reflex and its 5 HT control were largely carried out in rats, because the spinal reflex can be observed directly there and cannot be observed that way in humans. The step from that work to human physiology is an inference rather than a measurement, so this page does not present the mechanism as settled, because the regulator does not either.
The effect is a listed adverse effect elsewhere
This is the part that clarifies everything. The Medicines and Healthcare products Regulatory Agency records that with SSRIs, ejaculation may be delayed or abnormal, and lists this among very common and common adverse effects.
So the benefit sought in premature ejaculation is a documented unwanted effect in depression treatment. Nothing has been invented for this use. An existing antidepressant effect has been pointed at a different problem, which is exactly what off label prescribing means in practice.
Off label prescribing explained
Off label prescribing means using a licensed medicine outside the terms of its licence, for example for a condition it is not authorised to treat. It is lawful, it is common across medicine generally, and the responsibility shifts when it happens. Most SSRI use for premature ejaculation falls into this category.
What changes when a medicine is prescribed off label
| Licensed use | Off label use | |
|---|---|---|
| Assessed by the regulator for this purpose | Yes | No |
| Authorised product information covers this use | Yes | No |
| Effectiveness data for this use inside the licence | Yes | Not in the licence |
| Who carries the decision | Shared with the licence holder | The prescriber |
| Lawful | Yes | Yes |
The practical consequence is that the leaflet in the pack will not describe premature ejaculation at all, because that is not what the medicine is licensed for. That is expected rather than a mistake, and it is worth knowing before you open the box and worry.
What to ask before agreeing to an off label medicine
- Why this rather than the licensed option for my situation.
- What is actually known about this medicine for this specific use.
- What adverse effects should I expect, and which ones mean I should come back.
- How and when will this be reviewed.
- What happens if I want to stop, including how withdrawal would be managed.
A prescriber choosing an off label medicine should be able to answer all five. Asking is not a challenge to their judgement, it is the conversation the decision deserves.
Which SSRIs are used, and how
The National Institute for Health and Care Excellence records longer acting SSRIs used beyond their licences and taken daily, alongside the licensed short acting one taken before an occasion. Clomipramine, a tricyclic rather than an SSRI, and tramadol also appear among the off label options.
| Option | Class | Licence position | How it is used |
|---|---|---|---|
| Dapoxetine | Short acting SSRI | Licensed for premature ejaculation, men 18 to 64 | Before an occasion |
| Paroxetine, sertraline, fluoxetine, citalopram | Longer acting SSRIs | Unlicensed for this use | Daily |
| Clomipramine | Tricyclic antidepressant | Unlicensed for this use | Daily |
| Tramadol | Opioid analgesic | Unlicensed for this use | Before an occasion |
Every one of those medicines is prescription only, and every one except dapoxetine is being used outside its licence when it is used for this. The full range of PE treatments includes topical options that work in a completely different way.
Which SSRI works best?
There is no answer to that in the UK regulator record. The regulator states plainly that there are no randomised controlled trials comparing on demand dapoxetine with an active comparator such as daily use of a longer acting SSRI outside its licence.
Published pooled analyses of separate daily SSRI studies do exist outside that record, and paroxetine is the one most often reported as producing the largest increase in ejaculation latency, with citalopram usually reported as the smallest. Those comparisons come from pooling trials that were never run against each other, in different men under different conditions, so they indicate a rough ordering rather than establishing one.
The honest position is that the choice is made on your circumstances rather than on a league table. How often treatment is needed, what else you take, your medical history and how you respond are what actually decide it.
What the trials actually measured
Trials in this field measure intravaginal ejaculation latency time, usually shortened to IELT, recorded on a stopwatch. Everything published about how far a medicine improves ejaculation latency comes from that single measurement, which is worth remembering when you read a claim about confidence or satisfaction.
What the licensed medicine produced
The evidence is a pooled analysis of 5 phase III trials involving 6,081 men, run over 9 to 24 weeks. This was a fixed dose design, comparing two strengths against placebo rather than adjusting the amount for each man.
| Group | Latency at baseline | At 12 weeks | Gain |
|---|---|---|---|
| Placebo | 0.9 minutes | 1.9 minutes | 1.0 minute |
| Lower strength | 0.9 minutes | 3.1 minutes | 2.2 minutes |
| Higher strength | 0.9 minutes | 3.6 minutes | 2.7 minutes |
Both active groups showed a significant difference against placebo. The placebo group still gained a full minute, which the regulator treats as roughly the minimum clinically important change, so the improvement here is a modest one. Anyone quoting a much larger figure for any option is not quoting this evidence.
What has never been measured
No comparative study puts these medicines against each other for this use. No meta analysis of head to head trials exists, because those trials do not. No systematic review in the regulator record ranks them, and no long term study follows men using them for years. That absence is the reason this page refuses to name a single option as best.
On demand compared with daily use
The licensed short acting SSRI is taken before an occasion. Longer acting SSRIs used beyond their licence are taken daily, and the reason is pharmacological rather than a matter of preference. The National Institute for Health and Care Excellence sets it out directly: because longer acting SSRIs have a longer onset of action than the shorter acting dapoxetine, daily dosing is required.
| On demand short acting SSRI | Daily longer acting SSRI | |
|---|---|---|
| Drug class | Selective serotonin reuptake inhibitor | Selective serotonin reuptake inhibitor |
| Licensed for this condition | Yes | No |
| When an effect appears | Same day | Over weeks as a level builds |
| Clearance | Plasma levels under 5% of peak by 24 hours | A level is maintained |
| Exposure to the medicine | Only on days used | Continuous |
| Suits | Occasional or planned need | Frequent need |
| Stopping | Simply stop using it | Needs a planned withdrawal with your prescriber |
Reports outside the UK regulator record generally describe daily use as producing a larger delay than on demand use. Continuous exposure is the price of that, and it is why the last row matters as much as the second.
How SSRIs sit alongside other drug treatments
| Group | Example | Route | Licence position for this use |
|---|---|---|---|
| SSRIs | Dapoxetine, and other SSRIs used daily | Oral | One licensed, the rest unlicensed |
| Tricyclic antidepressants | Clomipramine | Oral | Unlicensed |
| Opioid analgesic | Tramadol | Oral | Unlicensed |
| Topical anaesthetics | Lidocaine and prilocaine preparations | Applied to the skin | Recorded as used beyond the licence |
Tricyclics act on serotonin as well but are an older class with a broader effect. Topical anaesthetics are a different proposition entirely, since they reduce sensation locally rather than acting through the bloodstream, which means they avoid the whole body effects of an SSRI.
Lifelong and acquired premature ejaculation
Which form you have does not change the drug options, but it does change what a realistic result looks like. Lifelong premature ejaculation has been present since a man first became active, so there is no earlier baseline to return to and an SSRI is being asked to produce something new rather than restore something lost.
Acquired premature ejaculation develops after a period of normal control, and it is the form where an identifiable change may sit behind the pattern, including a new medicine, alcohol intake, mood or thyroid function. Finding and dealing with that comes first, because it may remove the need for treatment, and it is also the form where the odds of lasting improvement are better.
Behavioural therapy alongside an SSRI
Behavioural therapy and an SSRI are frequently combined rather than treated as alternatives, and the regulator records that behavioural techniques have demonstrated benefit in premature ejaculation.
A medicine raises the threshold while it is present. Behavioural therapy trains recognition of the build up, so the ability stays with you. No trial in the regulator record has compared the two, so neither can be described as the more effective.
Taking an SSRI without depression
This is common and lawful. An SSRI prescribed for premature ejaculation is being used for its effect on the ejaculatory threshold, not to treat a mood condition you do not have. Two things follow.
First, the adverse effect profile of these medicines was characterised in people with depression and anxiety, not in men being treated for premature ejaculation. Whether the same profile applies identically is not something the published record establishes.
Second, the monitoring reasons still apply. The regulator advises that careful supervision during early treatment can help to identify unusual changes in behaviour, including worsening of symptoms, suicidal thoughts and behaviour, and aggression. That advice is not restricted to people with a diagnosed mood condition. If you notice a change in mood or thinking after starting any SSRI, contact your prescriber promptly rather than waiting for a scheduled review.
Adverse effects when used for ejaculation control
The adverse effects are those of the SSRI class, and the leaflet in your pack lists them for the specific medicine you have been given. That leaflet is the authoritative list, and it is worth reading before the first dose rather than after a surprise.
For the licensed short acting SSRI specifically, the regulator records nausea, dizziness and headache as very common, and diarrhoea, vomiting, fatigue, insomnia and anxiety among common effects. Those figures belong to that medicine.
The effect that is also the point
Delayed or abnormal ejaculation sits among the very common and common adverse effects of SSRIs. Here it is the intended effect, which creates an unusual situation and sets the practical limit on treatment.
Because the medicine acts on a threshold rather than setting a target, the effect is not finely adjustable, and an effect stronger than wanted is a recognised possibility rather than a fault. If that happens, it is a reason to go back to your prescriber rather than to change what you are taking yourself.
Why one SSRI's figures do not transfer to another
Each medicine in this class has its own profile. Reported rates of unwanted effects differ across the class, with fluoxetine often reported at the higher end. Transferring one medicine's numbers to another is the most common error in writing on this subject, and this page avoids it deliberately. Read the leaflet for the one you are actually prescribed.
Stopping an SSRI used for ejaculation control
Do not stop a daily SSRI abruptly. The regulator states that abrupt discontinuation of an SSRI can produce withdrawal symptoms, and advises patients to consult their clinician before suddenly reducing or stopping the dose. This applies whether the medicine was prescribed for depression or for premature ejaculation.
This is the single most important practical point on this page, and it is the one most often missing from pages about SSRIs for ejaculation control.
SSRI discontinuation symptoms
The regulator records that patients most commonly report dizziness, anxiety, insomnia and vivid dreams, tremor, paraesthesia, headache, nausea and lethargy. Also recorded are vomiting, electric shock sensations, flu like symptoms, agitation, emotional lability and confusion.
Paraesthesia means tingling or a pins and needles sensation. Emotional lability means rapid or unpredictable changes in mood.
How long withdrawal effects last
The regulator records that symptoms after sudden discontinuation usually last about one to two weeks and then resolve spontaneously, but that they can persist for longer in some patients.
How stopping is managed
The regulator's advice to clinicians is to reduce the dose gradually in staged intervals over about four weeks, with some patients requiring longer, and to review the patient for symptoms of withdrawal.
That is guidance for the person prescribing, not a plan for you to follow on your own. What this page gives you is the reason to book the conversation before you stop rather than after you have already run out. A man taking a daily SSRI for ejaculation control may reasonably decide he no longer needs it, and that decision feels different from stopping a medicine for a mood condition. The withdrawal effects do not know the difference.
SSRIs and alcohol
Alcohol comes up for two separate reasons. The first is direct: the product information for the licensed short acting SSRI advises against concomitant use with alcohol, and the regulator record notes advice about alcohol and recreational drugs alongside it.
The second is indirect and often missed. Alcohol shortens timing temporarily in men with no underlying condition at all, so heavy drinking can produce exactly the pattern the medicine is being taken to address. If alcohol is a regular feature, saying so during your assessment changes what the honest answer is.
Who these medicines are not suitable for
The licensed short acting SSRI is contraindicated in significant cardiac conditions, in a history of mania or severe depression, and in moderate to severe liver impairment. It is contraindicated alongside other serotonin reuptake inhibitors, tricyclics, monoamine oxidase inhibitors, lithium, linezolid, tramadol, St John's Wort, triptans, certain antifungals and PDE5 inhibitors.
That last one catches people out. If you take a medicine for erectile dysfunction, say so, because the two conditions are not treated at the same time. Where both are present, erectile dysfunction is normally addressed first, and treating it can change what the premature ejaculation picture looks like. Reviewing the ED treatments available shows why the two are handled separately.
Anyone already taking an antidepressant should raise it before anything is added, since combining serotonergic medicines is the specific situation these contraindications exist to prevent.
Getting assessed properly
Any SSRI used for premature ejaculation requires a consultation reviewed by a prescriber, whether it is the licensed one or an unlicensed option. The assessment is what makes the supply lawful and appropriate, and it is history led rather than test led.
The questions cover your age, cardiac history, mental health history, liver and kidney function, every other medicine you take including anything bought without a prescription, alcohol intake, and how you react to standing up. Anyone treated for high blood pressure should mention it, since the licensed medicine can lower blood pressure on standing.
Medical disclaimer
This page is general information, not medical advice, and gives no doses, schedules or tapering plans. These medicines are prescription only and should be used only under the supervision of an appropriately qualified prescriber. Always read the patient information leaflet supplied with your medicine, and report any suspected side effect through the MHRA Yellow Card scheme.
